Clinical Trials
30 trialsPEACH
Royal Marsden NHS Foundation Trust
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
NYU Langone Health
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
[18F]-AraG PET Imaging in LA HNSCC
Indiana University
OMET
Groupe Oncologie Radiotherapie Tete et Cou
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute
PembroMetaRT
UNICANCER
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
iCHRTL
Maria Sklodowska-Curie National Research Institute of Oncology
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
University of Chicago
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
LM-HNSCC
ChineseAMS
RESGEX
Glycotope GmbH
ADHERE
European Organisation for Research and Treatment of Cancer - EORTC
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
Swiss Cancer Institute
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx
Radiation Therapy Oncology Group
Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery
Radiation Therapy Oncology Group
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
SWOG Cancer Research Network